德展大健康股份有限公司 监事会对公司 2024 年度内部控制自我评价报告的意见 二〇二五年四月二十九日 公司监事会对董事会出具的《2024 年度内部控制自我评价报告》、公司内部 控制制度的建设和运行情况进行了监督。监事会认为公司内部控制组织机构设置 完整、科学，内控体系完备有效，公司内部控制重点活动的执行及监督充分有效。 公司内部控制自我评价报告客观、真实地反映了公司内部控制制度的建设及运行 情况。 德展大健康股份有限公司监事会 根据《中华人民共和国公司法》《上市公司治理准则》《深圳证券交易所股 票上市规则》《企业内部控制基本规范》（财会〔2008〕7 号）、《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，德 展大健康股份有限公司（以下简称"公司"）监事会对公司《2024 年度内部控制 自我评价报告》发表意见如下： ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 德展大健康股份有限公司（以下简称"公司"、"德展健康"）第八届董事 会第三十一次会议的通知已于 2025 年 4 月 13 日以电子邮件方式发出；公司于 2025 年 4 月 27 日 10:00 在公司北京会议室以现场方式召开。本次会议应参加会 议董事 9 人，实际参加会议董事 9 人。会议由董事长魏哲明先生主持，公司全体 监事及高管列席了本次会议。本次会议的召集、召开符合《公司法》及《公司章 程》的规定。 二、董事会会议审议情况 （一）关于公司 2024 年度总经理工作报告的议案 依据《公司法》等法律、法规、规范性文件及《公司章程》的规定，公司总 经理对 2024 年全年工作情况进行总结，并作《2024 年度总经理工作报告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 证券代码：000813 证券简称：德展健康 公告编号：2025-023 德展大健康股份有限公司 第八届董事会第三十一次会议决议公告 该议案审议获得通过。 《2024 年度总经理工作报告》主要内容详见公司同日在 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-025 德展大健康股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 27 日，德展大健康股份有限公司（以下简称"公司"）召开第 八届董事会第三十一次会议，会议以 9 票同意，0 票反对，0 票弃权，审议通过 了《关于公司 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年 度股东大会审议。现将具体情况公告如下： 一、2024 年度利润分配预案基本情况 根据中兴财光华会计师事务所（特殊普通合伙）出具的 2024 年度审计报告， 2024 年度公司合并口径期初未分配利润为 3,933,981,143.16 元，本期合并口径 实现归属于母公司股东的净利润为-20,413,065.61 元，截至 2024 年末公司合并 口径未分配利润为 3,913,568,180.55 元。2024 年母公司期初未分配利润为- 357,451,735.26 元，母公司本期实现净利润为-83,630,608.28 元，提取法定 ...

前十大流通股东累计持有： 121645.01万股，累计占流通股比： 56.2%，较上期变化： -9701.57万 股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 上海岳野股权投资管理合伙企业(有限合伙) | 41413.81 | 19.13 | 不变 | | 新疆凯迪投资有限责任公司 | 40974.84 | 18.93 | 不变 | | 美林控股集团有限公司 | 20740.25 | 9.58 | -8632.77 | | 新疆凯迪矿业投资股份有限公司 | 10403.94 | 4.81 | 不变 | | 新疆金融投资(集团)有限责任公司 | 2280.19 | 1.05 | 不变 | | 曹乐生 | 1509.85 | 0.70 | -312.08 | | 香港中央结算有限公司 | 1366.29 | 0.63 | -467.68 | | 宋湘沙 | 1147.77 | 0.53 | -177.40 | | 王赫 | 907.50 | 0.42 | 新进 | | 南方中证1000ETF | 900.57 | 0 ...

按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了德展大健康股份有限公司（以下简称"德展健康"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 德展大健康股份有限公司 中兴财光华审专字（2025）第 226018 号 内部控制审计报告 中兴财光华审专字(2025)第226018号 德展大健康股份有限公司全体股东： 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控 制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是德展 健康董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发 表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，德展健康于2024年12月31日按照《企业内部控制基本规范》和 相 ...

德展大健康股份有限公司 中兴财光华审会字（2025）第 226019 号 目录 | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 6-8 | | 合并及公司利润表 | 9-10 | | 合并及公司现金流量表 | 11-12 | | 合并及公司股东权益变动表 | 13-20 | | 财务报表附注 | 21-105 | 审计报告 中兴财光华审会字(2025)第 226019 号 德展大健康股份有限公司全体股东： 一、审计意见 我们审计了德展大健康股份有限公司（以下简称德展健康）财务报表，包 括 2024年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、 合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了德展健康 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年度的 合并及公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥89,277,784.01, a decrease of 11.82% compared to ¥101,250,441.65 in the same period last year[5]. - The net loss attributable to shareholders for Q1 2025 was ¥22,114,871.36, representing a 31.60% increase in loss from ¥16,805,072.84 in the previous year[5]. - The basic and diluted earnings per share for Q1 2025 were both -¥0.0104, a decline of 33.33% from -¥0.0078 in the same period last year[5]. - The net loss for the company was ¥29,276,212.82, which is a 35.45% increase from a loss of ¥21,613,891.55 in the same period last year, attributed to decreased interest income and increased credit impairment losses[10]. - Operating profit for the current period was -¥25,695,994.02, compared to -¥16,623,167.08 in the previous period, indicating a worsening of 54.5%[28]. - Net profit for the current period was -¥29,276,212.82, compared to -¥21,613,891.55 in the previous period, representing an increase in losses of 35.5%[28]. Cash Flow and Assets - The net cash flow from operating activities decreased by 20.60% to ¥18,042,709.30 from ¥22,723,297.27 year-on-year[5]. - The net cash flow from investing activities decreased by 82.21% to -¥37,670,373.09, compared to -¥20,673,911.95 in the previous year, mainly due to increased cash payments for fixed assets and intangible assets[10]. - The company’s cash and cash equivalents increased to 2,565,530,124.91 CNY from 2,530,699,274.17 CNY, reflecting a growth of approximately 1.4%[21]. - Cash flow from operating activities generated a net cash inflow of ¥18,042,709.30, down from ¥22,723,297.27 in the previous period, a decrease of 20.5%[31]. - Cash and cash equivalents at the end of the period totaled ¥2,480,454,564.29, a slight decrease from ¥2,731,014,590.64 in the previous period[33]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 65,376[13]. - The largest shareholder, Shanghai Yueye Equity Investment Management Partnership, holds 19.13% of shares, totaling 414,138,066 shares, with 25,250,000 shares frozen[13]. - The second largest shareholder, Xinjiang Kaidi Investment Co., Ltd., holds 18.93% of shares, totaling 409,748,445 shares, with 143,000,000 shares pledged[13]. - The top three shareholders collectively hold over 47% of the company's shares[13]. - The company has a repurchase account holding 28,567,500 shares, representing 1.32% of total shares[15]. - The company is conducting multiple rounds of public auctions for shares held by major shareholders, with recent auctions resulting in the successful sale of 25,250,000 shares[16]. - The report indicates that there are no changes in the top 10 shareholders due to securities lending or borrowing activities[16]. - The company has not issued any preferred shares or disclosed any preferred shareholders[16]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥5,355,877,868.80, an increase of 0.68% from ¥5,319,833,620.49 at the end of the previous year[5]. - The company’s total liabilities increased to 220,204,515.49 CNY from 154,884,054.36 CNY, representing a significant rise of approximately 42%[23]. - The company’s long-term borrowings amounted to 40,000,000.00 CNY, which was previously zero, indicating new financing activities[23]. - The company’s inventory increased to 209,630,292.48 CNY from 197,873,887.61 CNY, showing a growth of about 5.4%[22]. - The company’s accounts receivable decreased to 217,755,087.09 CNY from 242,227,524.74 CNY, reflecting a decline of approximately 10.1%[21]. Research and Development - The company signed a strategic cooperation framework agreement with Baoshihua Pharmaceutical Technology (Beijing) Co., Ltd. to enhance its health service system[19]. - The company’s subsidiary received approval for a clinical trial for a new drug targeting HPV-related conditions, showcasing ongoing R&D efforts[19]. - Research and development expenses for the current period were ¥10,024,839.12, down from ¥10,877,646.84 in the previous period, a decrease of 7.8%[28]. Other Income and Expenses - The company reported a significant increase of 96.91% in other income to ¥2,066,921.45, primarily due to increased government subsidies[10]. - Investment losses for Q1 2025 were ¥3,976,605.05, a 124.02% increase compared to losses of ¥1,775,111.21 in the previous year, mainly due to a decline in net profits from joint ventures[10]. - Total operating costs decreased to ¥99,442,024.53 from ¥106,513,804.78, reflecting a reduction of 6.3%[27].

Corporate Governance and Compliance - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[5] - The company has a structured governance framework with a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management[140] - The company is committed to maintaining compliance with laws and regulations regarding corporate governance and operations[141] - The company emphasizes the importance of protecting the rights of all shareholders, particularly minority shareholders, in its governance practices[139] - The company has established a market value management system to enhance its market value management practices[136] - The company has not reported any competitive conflicts with its controlling shareholder[144] - The company has a clear strategy for maintaining independence in business operations, personnel, assets, and finances[142] - The company has not implemented any employee stock ownership plans or other employee incentive measures during the reporting period[180] - The company has committed to ongoing monitoring and evaluation of risk control measures to ensure their effectiveness and compliance with established policies[183] - The company has conducted various research and communication activities with institutional investors to discuss operational conditions and R&D progress[134] Financial Performance - The company's operating revenue for 2024 was ¥466,485,016.50, a decrease of 6.34% compared to ¥498,088,171.28 in 2023[19] - The net profit attributable to shareholders for 2024 was -¥20,413,065.61, representing a decline of 124.50% from ¥83,314,246.81 in 2023[20] - The cash flow from operating activities for 2024 was -¥14,589,208.64, a significant drop of 111.41% compared to ¥127,872,780.78 in 2023[20] - The basic earnings per share for 2024 was -¥0.0095, down 124.87% from ¥0.0382 in 2023[20] - Total assets at the end of 2024 were ¥5,319,833,620.49, a decrease of 1.09% from ¥5,378,612,557.62 at the end of 2023[20] - The net assets attributable to shareholders at the end of 2024 were ¥5,158,023,472.59, down 1.53% from ¥5,237,902,679.94 at the end of 2023[20] - The company reported a negative net profit for the most recent accounting year, indicating uncertainty about its ability to continue as a going concern[21] - The company reported a net profit of -20,413,065.61 CNY for the fiscal year 2024, with an initial undistributed profit of 3,933,981,143.16 CNY[178] Research and Development - The company has a dedicated R&D platform with approximately 200 high-educated professionals, accounting for 20% of total employees, focusing on both technical improvements and new drug development[61] - R&D investment for 2024 reached CNY 78,203.1 million, a year-on-year increase of 53.05%, accounting for 16.76% of operating revenue, up 6.50 percentage points from the previous year[69] - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for new technology development[161] - The company has completed three pharmacodynamic studies and two mechanism studies for the CBD project aimed at treating pulmonary hypertension[88] - The company is developing a new drug for pancreatic cancer, having secured multiple patent rights across various countries[89] - The company is on track to launch a collagen product for post-surgical recovery by 2024, with ongoing trials for other cosmetic peptides[89] Market and Sales Performance - The total market size for lipid-regulating agents in China exceeded 20 billion yuan in 2023, with a year-on-year growth of 0.10%[30] - The retail market for oral lipid-regulating agents in China grew by 12.37% year-on-year in the first three quarters of 2024, with total sales exceeding 5 billion yuan[35] - The sales of atorvastatin calcium tablets reached 6.07 billion yuan in 2023, maintaining its position as the top product in the cardiovascular drug market[38] - The company is actively enhancing its OTC market presence and collaborating with strategic partners to promote "Alo" in retail markets[55] - The company is expanding its product matrix and exploring new market opportunities to drive growth and enhance its competitive position[56] Environmental Compliance - The company is compliant with multiple environmental protection laws and regulations, including the Environmental Protection Law and the Solid Waste Pollution Prevention Law[190] - The company holds a valid pollution discharge permit effective from June 12, 2024, to June 11, 2029[191] - The company has established emergency response plans for environmental incidents, with documentation filed with local authorities[192] - The company reported emissions of nitrogen oxides at 2 units with a concentration of 80 mg/Nm3, complying with the standard of 100 mg/Nm3[193] - The company has successfully completed environmental protection acceptance for its construction projects[192] Strategic Initiatives - The company is actively exploring new business areas, including biopolypeptides and medical services, with some segments already producing end products[43] - The company aims to reshape its competitiveness through a technology innovation strategy, focusing on biopharmaceuticals and expanding into the health industry[65] - The company plans to enhance shareholder returns through a three-year shareholder return plan (2023-2025) to balance interests between the company and its shareholders[177] - The company plans to use between 200 million and 300 million RMB of its own funds for share repurchases to enhance investor returns, with ongoing repurchase activities expected in 2025 based on market conditions[179] Risk Management - The company has identified and quantified risks in financial, investment, and compliance areas, establishing a comprehensive risk prevention mechanism to support stable development[182] - The company faces risks from market and policy changes, particularly due to the ongoing reforms in drug procurement and stricter regulations[132] - Rising production costs due to raw material prices and logistics are a concern, prompting the company to optimize supplier management and production technology[132] Employee Management - The total number of employees at the end of the reporting period was 1,054, with 435 in production, 179 in sales, and 202 in technical roles[171][172] - The company has established a three-dimensional dynamic compensation system focused on value creation and performance-driven principles[173] - The training plan for 2024 includes 24 different training programs, covering areas such as GMP regulations, financial management, and quality management systems[174][175]

Core Viewpoint - The announcement from 德展大健康股份有限公司 details the completion of share transfers involving significant shareholders, 上海岳野 and 美林控股, without affecting the company's control or operations [1][2][3]. Share Transfer Summary - 上海岳野 completed the auction transfer of 25,250,000 shares, representing 1.17% of the total share capital, reducing its holding from 19.13% to 17.96% [2]. - The shares were auctioned on the 京东 judicial auction platform, and the transfer was completed in compliance with legal regulations [2]. - The new shareholder is restricted from selling the acquired shares within six months [2]. Forced Reduction Summary - 美林控股 underwent a forced reduction of 15,127,500 shares due to a default in a stock pledge repurchase agreement, with a total of 21,363,800 shares executed, accounting for 0.99% of the total share capital [3]. - The forced execution price ranged from 3.15 to 3.48 yuan per share [3]. - 美林控股 is not a controlling shareholder, and this reduction will not impact the company's governance or operations [3]. Commitments and Compliance - 上海岳野 is fulfilling its commitment to reduce and regulate related party transactions without any violations [3]. - 美林控股 is also adhering to its commitments, although there is a dispute regarding performance commitments with 新疆凯迪投资, which has led to an arbitration application [3].

证券代码：000813 证券简称：德展健康 公告编号：2025-021 德展大健康股份有限公司 关于持股 5%以上股东股份拍卖过户完成及 被动减持完成的公告 股东美林控股集团有限公司、上海岳野股权投资管理合伙企业（有限合伙） 保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 德展大健康股份有限公司（以下简称"公司"）于近日收到公司持股 5%以 上股东上海岳野股权投资管理合伙企业（有限合伙）清算组（以下简称"上海岳 野"）出具的《股票拍卖过户告知函》，获悉其在第三次拍卖股份中被竞拍成功 的公司 25,250,000 股股份已于近日完成过户登记手续，上述股份占公司目前总 股本比例为 1.17%，占剔除公司回购专用账户股份数量后的公司总股本比例为 1.18%1。同时，根据公司持股 5%以上股东美林控股集团有限公司（以下简称"美 林控股"）发来的《关于司法强制执行完成的告知函》，其前期拟被司法强制执 行的股份已被执行完毕。此次共计被执行股份 21,363,800 股，占公司总股本的 比例为 0.99%，占剔除公司回购 ...